Singapore markets closed

Swedish Orphan Biovitrum AB (B6E.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
20.09-0.32 (-1.57%)
At close: 08:04AM CEST
Full screen
Previous close20.41
Open20.09
Bid20.35 x 100000
Ask20.95 x 100000
Day's range20.09 - 20.09
52-week range15.03 - 24.12
Volume0
Avg. volume1
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?

    Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Zacks

    Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top

    Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.

  • Reuters

    Drugmaker Sobi books profit fall on restructuring, Russia

    Swedish Orphan Biovitrum (Sobi) on Thursday reported a smaller-than-expected first-quarter operating profit and said sales grew in emerging markets for its drug Kineret for the treatment of COVID-19. The rare disease drugmaker's operating profit fell to 776 million crowns ($78.6 million) from 1.03 billion and missed the 1.16 billion expected by analysts polled by Refinitiv. The group, which sells drugs targeted at haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, booked restructuring costs of 507 million and a 157 million provision for expected credit losses in Russia.